CVS Health
CVS

$58.41

0.07%

Market Cap: $73.5B

About: CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.

Employees: 300,000

Consumer Discretionary Drug Stores & Proprietary Stores

0

Funds holding %

of 6,710 funds

0

Analysts bullish %

of 10 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

29% more call options, than puts

Call options by funds: $1.63B | Put options by funds: $1.26B

0.68% more ownership

Funds ownership: 80.93% [Q1] → 81.61% (+0.68%) [Q2]

12% less funds holding

Funds holding: 2,120 [Q1] → 1,857 (-263) [Q2]

25% less capital invested

Capital invested by funds: $81.1B [Q1] → $60.6B (-$20.5B) [Q2]

35% less funds holding in top 10

Funds holding in top 10: 40 [Q1] → 26 (-14) [Q2]

46% less repeat investments, than reductions

Existing positions increased: 550 | Existing positions reduced: 1,021

67% less first-time investments, than exits

New positions opened: 129 | Existing positions closed: 392

See Fund Rankings

Research analyst outlook

10 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$58

1%

downside

Avg. target

$62

7%

upside

High target

$68

16%

upside

10 analyst ratings

2 positive

20%

8 neutral

80%

0 negative

0%

Cantor Fitzgerald Sarah James 75% 1-year accuracy 86 / 115 met price target	6%upside $62	Neutral Reiterated	16 Sept 2024
Cantor Fitzgerald Sarah James 75% 1-year accuracy 86 / 115 met price target	6%upside $62	Neutral Reiterated	10 Sept 2024
RBC Capital Ben Hendrix 76% 1-year accuracy 41 / 54 met price target	16%upside $68	Outperform Reiterated	4 Sept 2024
Cantor Fitzgerald Sarah James 75% 1-year accuracy 86 / 115 met price target	6%upside $62	Neutral Reiterated	19 Aug 2024
Wells Fargo Stephen Baxter 77% 1-year accuracy 23 / 30 met price target	4%upside $61	Equal-Weight Maintained	12 Aug 2024

See Analyst Rankings

Financial journalist opinion

Based on 232 articles about CVS published over the past 30 days

The Motley Fool

4 Dividend Stocks to Double Up On Right Now

Verizon sports a fat dividend yield of 6.6% and plenty enough cash flow to cover it. Financial services powerhouse Citigroup offers a more modest but still solid 3.6% yield.

4 Dividend Stocks to Double Up On Right Now

CVS ALERT: Bragar Eagel & Squire, P.C. is Investigating CVS Health Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against CVS Health Corporation (NYSE: CVS) on behalf of long-term stockholders following a class action complaint that was filed against CVS on July 12, 2024 with a Class Period from May 3, 2023 to April 30, 2024. Our investigation concerns whether the board of directors of CVS have breached their fiduciary duties to the company.

CVS ALERT: Bragar Eagel & Squire, P.C. is Investigating CVS Health Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

CVS Health Corporation Is Being Sued For Securities Law Violations And The Schall Law Firm Invites Investor Participation

LOS ANGELES, CA / ACCESSWIRE / September 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 3, 2023 and April 30, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 10, 2024.

CVS Health Corporation Is Being Sued For Securities Law Violations And The Schall Law Firm Invites Investor Participation

Zacks Investment Research

Is CVS Health (CVS) a Buy as Wall Street Analysts Look Optimistic?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Is CVS Health (CVS) a Buy as Wall Street Analysts Look Optimistic?

CVS's Guide May Have Reached 'Kitchen Sink' Point

Despite deteriorating fundamentals and bad press, I bought a half-sized position in CVS due to its historical and relative cheapness, attractive yield, and potential for recovery. CVS trades below 9x forward PE, indicating it's priced for further deterioration, but it's historically and relatively cheap compared to peers like CI and UNH. CVS offers a 4.6% yield, making it an attractive income security, especially compared to treasury rates and other high-yield securities.

CVS's Guide May Have Reached 'Kitchen Sink' Point

A Securities Fraud Lawsuit Has Been Filed Against CVS Health Corporation And Shareholders With Losses Should Contact The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / September 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of 10(b) and 20(a) of the Securities Excange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 3, 2023 and April 30, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 10, 2024.

A Securities Fraud Lawsuit Has Been Filed Against CVS Health Corporation And Shareholders With Losses Should Contact The Schall Law Firm

CVS Health Corporation May Have Violated Securities Laws And The Schall Law Firm Wants Impacted Investors To Reach Out About A Case

LOS ANGELES, CA / ACCESSWIRE / September 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of 10(b) and 20(a) of the Securities Excange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 3, 2023 and April 30, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 10, 2024.

CVS Health Corporation May Have Violated Securities Laws And The Schall Law Firm Wants Impacted Investors To Reach Out About A Case

Zacks Investment Research

CVS Health (CVS) Rises Higher Than Market: Key Facts

The latest trading day saw CVS Health (CVS) settling at $57.98, representing a +0.78% change from its previous close.

CVS Health (CVS) Rises Higher Than Market: Key Facts

Stockholders Can Assist The Schall Law Firm In A Securities Fraud Lawsuit Against CVS Health Corporation

LOS ANGELES, CA / ACCESSWIRE / September 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of 10(b) and 20(a) of the Securities Excange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 3, 2023 and April 30, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 10, 2024.

Stockholders Can Assist The Schall Law Firm In A Securities Fraud Lawsuit Against CVS Health Corporation

3 Overlooked Stocks With Strong Value and Dividend Potential

Certain stocks stand out as attractively priced and well-positioned for potential appreciation for value investors focused on long-term growth with a defensive approach. While not isolated from risks and challenges, the three companies discussed below trade at favorable valuations based on P/E ratios and earnings growth and offer the added benefit of dividend income, making them appealing to those seeking steady returns and compounding growth.

3 Overlooked Stocks With Strong Value and Dividend Potential

See News Rankings